Breaking research presented at ADLM 2026 in Anaheim, California, suggests that machine learning (ML) could play an important role in enhancing the accuracy of a standard blood test used to diagnose rare tumors that form in or near the adrenal glands. The study also highlights the complexity of using ML models in laboratory medicine. As healthcare strives to harness the power of ML, this research could guide labs in rigorously validating their ML algorithms by illustrating the kinds of pitfalls they need to look out for.
Plasma-free metanephrines are the recommended first-line test for detecting masses known as pheochromocytomas and paragangliomas (PPGL), which cause the body to overproduce stress hormones. Left untreated, PPGL can cause heart problems, headaches, high blood pressure, and other issues.
While the metanephrine test effectively detects people who have PPGL, it does less well at ruling out everyone who doesn't have the condition. That's because mild elevations in metanephrines — which are metabolites derived from stress hormones — are often seen in patients who do not have these tumors, leading to false-positive results.
The researchers tested several ML algorithms to assess whether, and how much, they could bolster accuracy by reducing the likelihood of these false positives. They analyzed data from 20,516 adults who underwent metanephrine testing at Samsung Medical Center between 2011 and 2024. Of the 19,797 patients tested who ultimately did not have PPGL, 25.2 per cent demonstrated elevations in metanephrine that could trigger a false-positive result.
"Our initial machine-learning models suggested that combining plasma metanephrine results with structured clinical information from the electronic health record could improve real-world discrimination," said Se-eun Koo, one of the study's co-authors and a clinical chemistry fellow in the department of laboratory medicine and genetics at Samsung Medical Center in Seoul, South Korea.
Specifically, Koo and co-author Dr. Soo-Youn Lee found that, while metanephrine showed good reliability as a clinical marker, integrating ML to assess relevant clinical context — including kidney and urine biomarkers, patients' medications, and the presence of other diseases — appeared to boost the test's performance to make it excellent.
